Patents by Inventor Kirk Robarge

Kirk Robarge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor
    Patent number: 5663166
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: September 2, 1997
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor
    Patent number: 5565449
    Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 15, 1996
    Assignee: Genentech, Inc.
    Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
  • Tricyclic inhibitors of the GPII.sub.b III.sub.a receptor
    Patent number: 5493020
    Abstract: A trycylic benzodiazepine derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.
    Type: Grant
    Filed: July 29, 1993
    Date of Patent: February 20, 1996
    Assignee: Genentech, Inc.
    Inventors: Brent K. Blackburn, Kirk Robarge, Todd C. Somers